GIMBHI’s daily mental health update — 05/14/26

📊 LifeStance Health Q1 2026 earnings show margin inflection at outpatient mental health scale (GIMBHI) — 05/14/26
TL;DR: LifeStance reported $403.5M revenue (21% YoY) and $51.1M adjusted EBITDA (47% YoY) on 2.5M visits across 8,349 clinicians, signaling that scaled outpatient mental health can generate real margins, while $49.1M in buybacks vs. $4.4M in M&A suggests sub-scale therapy practices remain overpriced.

🎓 TimelyCare acquires Alongside to add AI coaching to student mental health platform (TimelyCare) — 05/04/26
TL;DR: Fort Worth-based TimelyCare, which serves nearly 500 campuses, acquired Alongside, a clinician-designed AI coaching platform used by 200+ schools, to extend its virtual care model into early-intervention support for everyday stress with safety

💰 Wisdom Ventures closes oversubscribed $77.7M Fund II to back tech-enabled wellbeing startups (Wisdom Ventures) — 05/07/26
TL;DR: San Francisco-based Wisdom Ventures closed a $77.7M Fund II to write $1M–$5M checks into ~40 early-stage AI startups advancing health, wellness, and human connection, with LPs including Reid Hoffman, Evan Sharp, and Stewart Butterfield, and Dr. Vivek Murthy joining as Senior Venture Partner.

💰 Atar Capital reportedly putting outpatient behavioral health provider Clarvida up for sale (Ashleigh Hollowell, Behavioral Health Business) — 05/11/26
TL;DR: Atar Capital is in second-round sale of Clarvida, a Medicaid-focused behavioral health provider operating in 17 states with 60,000 yearly patients.

💼 Federal loan restrictions and funding cuts threaten the behavioral health workforce (Laura Lovett, Behavioral Health Business) — 05/07/26
TL;DR: New loan caps and $2B SAMHSA cuts threaten therapists and social workers as 40% of US lives in mental health shortage areas.

💊 PETRUSHKA web tool cuts antidepressant dropouts and improves primary care depression outcomes (John J. Miller, MD, Psychiatric Times) — 05/07/26
TL;DR: Oxford-led tool halved 8-week antidepressant dropouts (16% vs 28%) and improved 24-week depression and anxiety scores in primary care.

🤝 Pine Tree-backed mental health provider Altior Healthcare may hit M&A market next (Chris Larson, Behavioral Health Business) — 05/07/26
TL;DR: Altior Healthcare expected to enter sale process amid surging 2026 behavioral health M&A activity following UHS-Talkspace and MKH-Haven deals.

🪖 FDA clears MIND1 trial of NRX-101 plus robotic TMS for suicidal treatment-resistant depression (Leah Kuntz, Psychiatric Times) — 05/06/26
TL;DR: FDA approved NRx Pharmaceuticals’ Phase 2/3 MIND1 trial pairing NRX-101 with robotic TMS for treatment-resistant depression, including military sites.